2028 - Pharmacist Digest

STAT+: Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded

STAT

NOVEMBER 19, 2024

patent expires in 2028. For Merck, the new under-the-skin, or subcutaneous, formulation of Keytruda could represent a major way of holding on to a larger share of Keytruda’s $25 billion in annual sales than would otherwise occur when the medicine’s U.S. It is the best-selling medicine in the world.

Immunity

Immunity Immunization

STAT+: Make America Healthy Again is ringing through statehouses across the U.S.

STAT

MARCH 26, 2025

Some of the new measures — like West Virginia’s landmark bill, signed into law Monday , banning most artificial dyes and two preservatives from sale in the state starting in 2028 — highlight how concern over the safety of the U.S. food supply is an increasingly nonpartisan issue.

Labelling

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

JUNE 26, 2025

Inclusion of Part B Drugs: Scope, Challenges, and Opportunities The addition of provider-administered therapies covered under Medicare Part B to the IPAY 2028 cycle introduces a fundamentally different reimbursement and care delivery context than that of pharmacy-dispensed Part D drugs.

Drug Pricing

Drug Pricing Communication Drug Development Documentation

STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more

STAT

NOVEMBER 19, 2024

patent expires in 2028. For Merck, the new under-the-skin, or subcutaneous, formulation could represent a major way of holding on to a larger share of Keytruda’s $25 billion in annual sales than would otherwise occur when a U.S.

EMA publishes EU strategy to 2028

European Pharmaceutical Review

OCTOBER 10, 2024

A draft joint EU network strategy to 2028 has been published by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA). The overarching theme of our updated strategy to 2028 is that of change – rapid, somewhat unpredictable but nonetheless full of promise.

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

OCTOBER 24, 2023

billion in 2028, according to a report by Arizton. percent up to 2028. percent between the forecast period: 2023 and 2028. percent between the forecast period 2023-2028. Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 Having been valued at $27.04 percent in 2022.

Packaging

Packaging Labelling Compounding Pharmaceutical Companies

STAT+: Grail announces layoffs as it looks to push forward blood-based cancer detection test

STAT

AUGUST 13, 2024

In a press release, the company said that the cuts would help it extend its cash reserves from the second half of 2026 into 2028. The Bay Area biotech brought in $32 million during the quarter but also reported a net loss of $1.6 Continue to STAT+ to read the full story…

Pharmaceutical data and analytics market to grow to $2.1 bn by 2028: GlobalData

Express Pharma

DECEMBER 13, 2024

billion by 2028, driven by data and content management, according to GlobalData. According to GlobalDatas latest report, Market and Opportunity Forecast to 2028, Data and Analytics 2024, the total global data and analytics market is forecast to increase at a compound annual growth rate (CAGR) of 9.5 per cent in 2028.

Compounding

STAT+: Bristol Myers to partner with BioNTech on experimental cancer drug

STAT

JUNE 2, 2025

BMS will also pay BioNTech up to $2 billion in annual payments through 2028. Bristol will pay $1.5 billion up front to BioNTech for a 50% share in the profits and losses from BNT327. BioNTech will then be eligible to receive up to $7.6 billion in additional development, regulatory, and commercial milestone payments.

Drug Development

Raman spectroscopy market expected to value $875m by 2028

European Pharmaceutical Review

SEPTEMBER 6, 2023

million by 2028, with a CAGR of 7.3 percent from 2023 to 2028. Between 2023 to 2028, the research suggested that a greater focus on drug development, growing requirement for spectroscopy via cloud-based platforms, alongside the industry’s need for precise and effective analytical methods, will drive the market.

Drug Development

Standalone Sandoz eyes $3bn in new product sales by 2028

pharmaphorum

JUNE 8, 2023

Standalone Sandoz eyes $3bn in new product sales by 2028 Phil.Taylor Thu, 08/06/2023 - 07:57 Bookmark this

STAT+: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug

STAT

MAY 14, 2024

Last December, the agency determined the confirmatory trial was not acceptable and asked the company to run yet another trial, which must be completed by February 2028.

Dosage

STAT+: Vertex Pharmaceuticals is considering relocating its headquarters

STAT

MARCH 25, 2024

With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood. Now, Vertex may be on the move again. Continue to STAT+ to read the full story…

Drug Development

STAT+: Merck to acquire Harpoon Therapeutics for $680 million

STAT

JANUARY 8, 2024

That could come as soon as 2028. The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug.

Immunity

Immunity Immunization

mRNA non-vaccine therapeutics to generate $2 billion by 2028

European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. billion during 2028.

Vaccines

Vaccines Immunity Immunization

STAT+: Brigham and Women’s exec opens up about the Dana-Farber Cancer Institute split, and what it means for the future of cancer care

STAT

SEPTEMBER 28, 2023

The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians. Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives.

Hospitals

STAT+: Which hospital systems will join Kaiser’s Risant next?

STAT

JUNE 3, 2024

Kaiser, which is both a health insurance company and a network of providers, said it wants to add at least five to six more health systems by 2028. Geisinger’s 10 hospitals and 1,700 employed physicians are now officially part of the group, known as Risant Health. Those other organizations are still a mystery.

Hospitals

Hospitals Health Insurance Companies

Alzheimer’s drug Leqembi expected to generate $12.9bn in sales by 2028

Pharmafile

MARCH 30, 2023

After receiving FDA approval in January 2023, Biogen/Eisai’s new Alzheimer’s disease Leqembi is expected to become a blockbuster, with a predicted $12.9bn predicted to be made in sales between 2023 and 2028. The drug is still awaiting approval in the EU and Japan, with these approvals potentially making it the top-selling Alzheimer’s drug.

STAT+: Amid divorce from Dana-Farber, Mass General Brigham touts its own cancer institute

STAT

OCTOBER 29, 2024

Beginning in 2028, Dana-Farber will end its long and nationally acclaimed adult oncology partnership with Brigham and Women’s Hospital. Instead, it will team up with Beth Israel Deaconess Medical Center to open a new freestanding 300-bed, $1.68 billion cancer hospital in the Longwood Medical Area.

Hospitals

STAT+: Pharmalittle: We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more

STAT

MAY 20, 2025

The FDA will hold two public meetings in July to discuss reauthorization of its use fee act programs for the fiscal year 2028-2032 period. The current legislative authority for the programs expires at the end of September 2027. Continue to STAT+ to read the full story…

Compounding

Compounding Diabetes

STAT+: Pharmalittle: We’re reading about Sarepta’s demand to censor a video, Roche fast-tracking an obesity pill, and more

STAT

JULY 29, 2024

Thomas Schinecker, chief executive of the pharmaceutical company, said its first obesity drugs would come to market “significantly faster than people are expecting,” potentially by 2028. The treatments, acquired in a $3.1 reduction in weight compared with a placebo after four weeks.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

STAT+: Pharmalittle: Merck ends late-stage trial for Keytruda in prostate cancer; doctor group says 60 Minutes segment on Wegovy was an ad

STAT

JANUARY 25, 2023

The data is a setback for Merck, which has been working to expand use of Keytruda, which has powered its growth for years but will lose exclusivity in 2028. The drug was being tested in combination with androgen deprivation therapy and Xtandi in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

GLP-1R gold rush: Emerging biotechs can challenge market leaders, says GlobalData

Express Pharma

JANUARY 14, 2025

Estimated to launch in 2028, this drug is forecast to deliver $2 billion in 2030, earning Viking a spot in the list of top 10 companies by GLP-1R sales, after the industry heavyweights: Novo Nordisk, Eli Lilly, and Amgen. This drug is expected to launch in 2028 and ultimately generate sales of $1.2 billion in 2030.

Diabetes

Keytruda fails lung and skin cancer trials, limiting further expansion

BioPharma Dive

AUGUST 29, 2024

The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion.

CMOs and Hybrid Companies Predicted to Hold 54% of Biologics Capacity in 2028, According to CPHI Annual Survey

PharmaTech

OCTOBER 8, 2024

According to the annual survey, four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which are expected to have 45% of all CMO capacity in Asia.

AbbVie’s tavapadon holds potential to become prominent treatment in dopamine agonist market: GlobalData

Express Pharma

DECEMBER 20, 2024

GlobalData expects tavapadon to enter the market in 2028, and despite its impressive efficacy data, the drugs success will likely be influenced by its safety profile.

Appeals court sides with Amgen in patent fight over psoriasis drug Otezla

BioPharma Dive

APRIL 20, 2023

With the court victory, the biotech giant could stave off a set of generic competitors for the top-selling drug until 2028.

Govt provides updates on measures to encourage domestic manufacturing

Express Pharma

DECEMBER 9, 2024

The scheme provides financial incentives for the manufacturing of notified products. PLI Scheme for Pharmaceuticals, with a financial outlay of Rs.

Immunity

Immunity Immunization

Fragile X syndrome market to quadruple to $111.9 million in US and Germany by 2030, forecasts GlobalData

Express Pharma

FEBRUARY 18, 2025

Zygel is expected to launch in Germany in 2028, whereas zatolmilast is not anticipated to launch in Germany during the forecast period. These therapies are set to represent the first treatments to be indicated for FXS.

Labelling

Incubators and innovation hubs: Accelerating entrepreneurship in life sciences

Express Pharma

NOVEMBER 30, 2024

The country’s health metrics, such as the growing burden of non-communicable diseases, rising life expectancy, malnutrition, and air pollution, present a further scope for innovations in life sciences to strengthen healthcare delivery estimated to reach $60 billion by FY 2028 (1).

Communication

Körber absorbs Wilhelm Bähren to expand pharma packaging toolbox

Outsourcing Pharma

DECEMBER 3, 2024

Discover how a strategic acquisition in pharma packaging is set to drive growth as the market aims to double by 2028

Packaging

NHS to receive ‘largest ever’ cash boost in spending review

The Pharmacist

JUNE 11, 2025

NHS funding to is to rise by 3% a year until 2028/29, the chancellor has announced today in her spending review. The government is providing a £29bn increase (£53bn cash increase) in annual NHS day-to-day spending from 2023/24 to 2028/29.

Germany largest revenue contributor in Europe’s LIMS market

European Pharmaceutical Review

MARCH 20, 2024

million by 2028. percent between 2022-2028, the research found. Based on the research, the US LIMS market is predicted to value $1 billion by 2028. According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 The market is growing at a CAGR of 10.16

Pharmaceutical excipients market to witness expansion

European Pharmaceutical Review

DECEMBER 4, 2023

billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. Moreover, the non-toxic nature of organic chemicals is expected to drive the organic chemicals sectors, ultimately boosting the pharmaceutical excipient market in the forecast period (2023 to 2028).

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

Responsible sourcing and manufacturing: Growing towards a sustainable future with Lonza

Express Pharma

JANUARY 17, 2025

By 2028, Lonza aims to ensure that 90 per cent of its spending comes from suppliers with sustainability scores and 67 per cent of Lonzas Scope 3 emissions are covered by suppliers with science-based targets, in alignment with Lonzas validated Scope 3 targets by the Science-Based Targets initiative (SBTi).

Dosage

Dosage Pharmaceutical Manufacturing Packaging Drug Development

Pharma’s data and analytics market forecast to reach to $2.1bn by 2028

Pharmaceutical Technology

DECEMBER 18, 2024

A new report identifies data content management as the primary driver of growth in the pharmaceuticals market.

Bharat Biotech and GSK pledge to lower malaria vaccine price under Gavi replenishment initiative

Express Pharma

JUNE 25, 2025

The companies confirmed a phased reduction in the vaccine’s price to below USD 5 by 2028. The full transition of manufacturing from GSK to Bharat Biotech is expected to be complete by 2028. The price reduction is enabled through increased production capacity, cost-effective manufacturing processes, and low-margin pricing strategies.

Vaccines

EMA and HMA Publish Joint Network Strategy to 2028

PharmaTech

MARCH 24, 2025

The EU medicines agencies network strategy, EMANS, is an update of the five-year strategy previously developed to cover the period 2021 to 2025.

Report: Oncology, Immunology Projected to Lead Global Spending From 2024 to 2028

Pharmacy Times

JANUARY 22, 2024

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

IU Health board OKs $214M for new hospital, cancer center

Beckers Hospital Review

JULY 11, 2025

” Construction on the hospital and cancer center is expected to kick off in 2026, with projected openings in 2028. . “We planted our flag early, confident in the community’s potential and committed to being part of its future.”

Hospitals

Report: Biotech Manufacturing Market to Reach $24.8 Billion by 2028

Pharmaceutical Commerce

SEPTEMBER 25, 2023

This would signify an 8.3% CAGR over the next five years.

Lilly, LA28 Olympic and Paralympic Games Announce Collaboration Through 2028

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

AstraZeneca and Sanofi Beyfortus to dominate RSV market in China: GlobalData

Express Pharma

JANUARY 31, 2024

GlobalData’s Respiratory Syncytial Virus (RSV) Forecast in Asia-Pacific Markets to 2028 reveals that Urban China will lead the Asia-Pacific (five growth markets*) market for RSV in 2028, accounting for 34.8 Hence, the approval addresses an urgent need for novel prophylactic treatment options for the pediatric population in China.”

Biogen to Establish New Global HQ and Innovation Hub in Massachusetts by 2028

PharmExec

MARCH 24, 2025

The facility, which is set to open amid Biogens 50th anniversary, will integrate research and development, technical operations, and commercial teams into one location.

STAT+: Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded

STAT+: Make America Healthy Again is ringing through statehouses across the U.S.

Trending Sources

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more

EMA publishes EU strategy to 2028

Europe’s pharmaceutical packaging market to value over $35bn by 2028

STAT+: Grail announces layoffs as it looks to push forward blood-based cancer detection test

Pharmaceutical data and analytics market to grow to $2.1 bn by 2028: GlobalData

STAT+: Bristol Myers to partner with BioNTech on experimental cancer drug

Raman spectroscopy market expected to value $875m by 2028

Standalone Sandoz eyes $3bn in new product sales by 2028

STAT+: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug

STAT+: Vertex Pharmaceuticals is considering relocating its headquarters

STAT+: Merck to acquire Harpoon Therapeutics for $680 million

mRNA non-vaccine therapeutics to generate $2 billion by 2028

STAT+: Brigham and Women’s exec opens up about the Dana-Farber Cancer Institute split, and what it means for the future of cancer care

STAT+: Which hospital systems will join Kaiser’s Risant next?

Alzheimer’s drug Leqembi expected to generate $12.9bn in sales by 2028

STAT+: Amid divorce from Dana-Farber, Mass General Brigham touts its own cancer institute

STAT+: Pharmalittle: We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more

STAT+: Pharmalittle: We’re reading about Sarepta’s demand to censor a video, Roche fast-tracking an obesity pill, and more

STAT+: Pharmalittle: Merck ends late-stage trial for Keytruda in prostate cancer; doctor group says 60 Minutes segment on Wegovy was an ad

GLP-1R gold rush: Emerging biotechs can challenge market leaders, says GlobalData

Keytruda fails lung and skin cancer trials, limiting further expansion

CMOs and Hybrid Companies Predicted to Hold 54% of Biologics Capacity in 2028, According to CPHI Annual Survey

AbbVie’s tavapadon holds potential to become prominent treatment in dopamine agonist market: GlobalData

Appeals court sides with Amgen in patent fight over psoriasis drug Otezla

Govt provides updates on measures to encourage domestic manufacturing

Fragile X syndrome market to quadruple to $111.9 million in US and Germany by 2030, forecasts GlobalData

Incubators and innovation hubs: Accelerating entrepreneurship in life sciences

Körber absorbs Wilhelm Bähren to expand pharma packaging toolbox

NHS to receive ‘largest ever’ cash boost in spending review

Germany largest revenue contributor in Europe’s LIMS market

Pharmaceutical excipients market to witness expansion

Responsible sourcing and manufacturing: Growing towards a sustainable future with Lonza

Pharma’s data and analytics market forecast to reach to $2.1bn by 2028

Bharat Biotech and GSK pledge to lower malaria vaccine price under Gavi replenishment initiative

EMA and HMA Publish Joint Network Strategy to 2028

Report: Oncology, Immunology Projected to Lead Global Spending From 2024 to 2028

IU Health board OKs $214M for new hospital, cancer center

Report: Biotech Manufacturing Market to Reach $24.8 Billion by 2028

Lilly, LA28 Olympic and Paralympic Games Announce Collaboration Through 2028

AstraZeneca and Sanofi Beyfortus to dominate RSV market in China: GlobalData

Biogen to Establish New Global HQ and Innovation Hub in Massachusetts by 2028

Stay Connected